BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1870382)

  • 1. A retrospective study on seven years of multiple drug treatment for paucibacillary and multibacillary leprosy, in Bayara General Hospital, Nigeria.
    Blok LM; Bloos LJ; van den Berg G
    Lepr Rev; 1991 Jun; 62(2):193-200. PubMed ID: 1870382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR).
    Penna GO; Pontes MAA; Talhari S; Gonçalves HS; Talhari C; Pessoa AS; Pedroza V; Bührer-Sékula S; Stefani MMA; Penna MLF
    Braz J Infect Dis; 2024; 28(2):103745. PubMed ID: 38697216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
    Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A trial of polychemotherapy of leprosy in the Dakar region. Initial observations on the acceptability of the protocols used].
    Millan J; Bodian M; Naudin JC; Diouf B; Boucher P; Ndoye B; Grosset J
    Acta Leprol; 1986; 4(1):19-35. PubMed ID: 3526792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months.
    Ji B
    Lepr Rev; 1998 Jun; 69(2):106-9. PubMed ID: 9715593
    [No Abstract]   [Full Text] [Related]  

  • 8. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.
    Pieters FA; Woonink F; Zuidema J
    Eur J Clin Pharmacol; 1988; 34(1):73-6. PubMed ID: 3360051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy.
    Soares DJ; Neupane K; Britton WJ
    Lepr Rev; 1995 Sep; 66(3):210-3. PubMed ID: 7500815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 13. Multidrug therapy regimen for leprosy.
    Firooz A
    J Am Acad Dermatol; 2006 Dec; 55(6):1115; author reply 1115. PubMed ID: 17110233
    [No Abstract]   [Full Text] [Related]  

  • 14. [Combination chemotherapy in leprosy].
    Leiker DL
    Ned Tijdschr Geneeskd; 1986 Oct; 130(43):1926-9. PubMed ID: 3774040
    [No Abstract]   [Full Text] [Related]  

  • 15. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
    Lockwood DN; Cunha Mda G
    Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
    Lim JT; Tan T
    Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of tests for monitoring drug compliance of leprosy out-patients under multi-drug therapy.
    Balakrishnan S; Kumar A; Rao BR; Patro TP
    Indian J Lepr; 1986; 58(4):555-9. PubMed ID: 3572097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guideline for the treatment of Hansen's disease in Japan (Second edition)].
    Goto M; Nogami R; Hatano K; Okano Y; Ishii N; Gidoh M; Ishida Y; Ozaki M;
    Nihon Hansenbyo Gakkai Zasshi; 2006 Sep; 75(3):191-226. PubMed ID: 17037376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.